The company’s lead clinical candidate, BTX-A51, is an oral small molecule, multi-kinase inhibitor designed to block a specific leukemic stem cell target (CK1α) as well as super enhancer targets ...

But with BTX now down to $7.75 after the name/ticker change yesterday, it's becoming attractive once again. The problem is that we don't know what the new NAV symbol for BTX is, so it's hard to ...